10-K: Lifecore Biomedical Restates Financials, Cites Material Weaknesses in Internal Controls

Lifecore Biomedical, Inc. has restated its financial statements for fiscal years 2021 and 2022 due to errors in accounting, revealing material weaknesses in internal controls.

Summary

• Lifecore Biomedical, Inc. has filed its annual report on Form 10-K, which includes a restatement of previously issued financial statements for fiscal years 2021 and 2022.
• The restatement was prompted by errors in the calculation of capitalized interest, valuation of inventories, and adjustments related to divested businesses.
• The company identified material weaknesses in its internal control over financial reporting, specifically in the areas of control environment, risk assessment, information and communication, and monitoring.
• These weaknesses led to errors in inventory valuation, capitalization of interest, revenue recognition, and presentation of operating costs.
• The company has implemented a plan to remediate these weaknesses, which includes engaging a third-party consultant.
• The company's revenue for fiscal year 2023 was $103.3 million, a decrease from $111.3 million in fiscal year 2022, primarily due to a decrease in CDMO sales.
• Gross profit for fiscal year 2023 was $28 million, down from $39.1 million in fiscal year 2022, due to decreased revenue and an unfavorable sales mix.
• The company incurred a loss on debt extinguishment of $23.7 million in fiscal year 2023 due to refinancing transactions with Alcon.
• The company's net loss for fiscal year 2023 was $99.6 million, compared to a net loss of $116.7 million in fiscal year 2022.
• The company has transitioned to a single reportable segment, Lifecore, following the divestiture of its Curation Foods business.

Sentiment

Score: 3

Explanation: The document reveals significant financial challenges and internal control weaknesses, leading to a negative outlook despite some positive strategic initiatives. The restatement and delays in reporting are major concerns.

Positives

• The company is actively working to remediate the identified material weaknesses in internal controls.
• The company has a strategic focus on the growth of its CDMO business.
• The company has a strong track record with global regulatory bodies.
• The company has made strategic capital investments in its CDMO business.

Negatives

• The company experienced a significant decrease in revenue and gross profit in fiscal year 2023.
• The company incurred a substantial loss on debt extinguishment.
• The company has identified material weaknesses in its internal control over financial reporting.
• The company has been in non-compliance with its credit agreements in the past.
• The company has experienced delays in filing its periodic reports with the SEC.

Risks

• The company's high leverage and contractual obligations may limit operational flexibility.
• Failure to remediate material weaknesses in internal controls could lead to misstated financial results.
• The company's reliance on a few large customers poses a risk to revenue stability.
• Increasing competition in the CDMO market could impact pricing and profitability.
• The company's relationship with Alcon as a significant customer and lender presents unique risks.
• The company's operations are subject to extensive government regulations.
• The company's strategic review process may not result in any future strategic transactions.
• The company's failure to timely file periodic reports with the SEC could lead to delisting from Nasdaq.

Future Outlook

The company is focused on driving profitable growth with product development and manufacturing of sterile injectable products and seeks to expand its presence in the CDMO marketplace by partnering with biopharmaceutical and biotechnology companies.

Management Comments

• Lifecore seeks to expand its presence in the CDMO marketplace by partnering with biopharmaceutical and biotechnology companies to bring their unique therapies to market.
• Lifecore's goal of continuing success will be to execute on its three strategic priorities: managing business development pipeline, maximizing capacity, and advancing product commercialization.

Industry Context

The company operates in the competitive and rapidly evolving CDMO market, facing competition from full-service contract manufacturers and large pharmaceutical companies. The company is focused on expanding its presence in the CDMO marketplace by partnering with biopharmaceutical and biotechnology companies to bring their unique therapies to market.

Comparison to Industry Standards

• The company's competitors include full-service contract manufacturers and large pharmaceutical companies, some of which have substantially greater financial, marketing, technical, and other resources.
• Some competitors have the ability to insource manufacturing, while others may acquire divested assets from pharmaceutical companies.
• The company's financial results are compared to those of 19 peer companies in the life sciences sector, with a focus on contract development and manufacturing organizations, contract research organizations, medical technology and device, commercial drug development or pharma, and healthcare.
• The company's goal is to target total compensation for executive officers at a level that is near the 50th percentile within the peer group.

Management Changes

Corporate Governance

Legal Proceedings

• The Chicago Regional Office of the SEC has issued a subpoena to the Company seeking documents and information concerning the Restatement.
• The company is involved in various legal proceedings and claims in the ordinary course of business.
• The company is negotiating a potential resolution of the DOJ's investigation into potential environmental and Foreign Corrupt Practices Act (FCPA) compliance matters.

Related Party Transactions

• The company had sales to Alcon Research, LLC, a related party, of $40.2 million in fiscal year 2023.
• The company entered into a Securities Purchase Agreement with entities affiliated with Wynnefield Capital, Inc., controlled by director Nelson Obus.
• The company issued Series A Convertible Preferred Shares to a group of qualified investors, including entities controlled by directors Christopher Kiper and Nelson Obus, and an entity that employs Dr. Calloway.
• The company entered into an Amended and Restated Supply Agreement with Alcon, a significant customer and lender.

Stakeholder Impact

• Shareholders may experience a decrease in share value due to the restatement and identified weaknesses.
• Employees may be affected by potential restructuring and changes in compensation.
• Customers may be impacted by potential delays or disruptions in product supply.
• Suppliers may be affected by changes in the company's financial stability.
• Creditors may be concerned about the company's high leverage and ability to meet its obligations.

Next Steps

• The company plans to remediate the identified material weaknesses in internal controls.
• The company will continue to execute on its three strategic priorities: managing business development pipeline, maximizing capacity, and advancing product commercialization.
• The company will continue to seek out opportunities to advance customers late-stage product development activities by supporting their clinical programs and commercial process scale-up activities.

Key Dates

Keywords

Lifecore Biomedical, financial restatement, material weaknesses, internal controls, CDMO, contract manufacturing, biomaterials, hyaluronic acid, debt, refinancing, Alcon, Curation Foods, discontinued operations